|
Archive 2002
Prescription Drug Market Performance, 2002 - 2003
Formulary Updates 2002
Posted December 23, 2002
Nova Scotia
December 2002 Bulletin, effective January 3, 2003
Highlights
New Benefits: Advair HFA, Biaxin and Biaxin XL, Dexlron, Infufer, Zyprexa;
Declined Products: Starlix;
Delisted Products: Ketalar Injectable;
New Inerchangeable Categories: Please see the bulletin for details;
Artificial Tear Product Review: Full Benefits: Gen Teal, Moisture Drops, Tears Naturale II,
Tear Drops, Hypotears, Duolube, Tear Gel;
Exception Status: Celluvisc, Refresh, Refresh Plus,
Tears Naturale Free, Refresh Tears;
Not Insured: Eyelube, Isopto Tears, Tears Naturale, Liquifilm,
Tears Plus, pms-Artificial Tears, pms-Artificial Tears Extra, Tears Naturale P.M.,
Hypotears (3.5g), Lacrilube, Bion Tears, Eyestil, Hyalshield, Theratears, Tears Encore;
Posted December 19, 2002
Manitoba
Bulletin - effective December 18, 2002
Highlights
Additions: Agenerase, Alti-salbutamol HFA, Apo-Cindamycin, Apo-Clobazam, Apo-Lamotrigine, Apo-Medroxy, Apo-Warfarin,
Clobetasol Propionate, Comtan, Flovent HFA, Gen-Propafenone, Kaletra, Pamidronate Disodium, pms-Morphine Sulfate SR, pms-Prednisolone,
ratio-Topisalic, Taro-Carbamazepine; Deletions: Apo-Loperamide, Diarr-eze, Imodium, Novo-Loperamide, pms-Loperamide, Rhoxal-Loperamide;
Amendment: Apo-Amoxi Clav;
New Special Authorizations: Gen-Nabumetone, Tracleer, Botox, Loperamide, Hectorol;
New Interchangeable Categories and Products and Deletions: See Bulletin for details;
Discontinued Products: Asendin, Fexicam, Inderal, Inflamase mild, Isordil, Neptazane, Novo-Timol, Orudis, Orudis E-50
Posted December 19, 2002
New Brunswick
Update dated December 20, 2002
Highlights
Interchangeable Product Additions: 16 durg products have been added (see update for details).
Note: Effective January 1, 2003 the sale of all salbutamol MDIs containing a chlorofluorocarbon
propellant is prohibited.
Posted December 16, 2002
British Columbia
Pharmacare Newsletter Decemer 13, 2002
Highlights
New Eligible Benefits: Apo-Lamotrigine, Apo-Methazolamide, Apo-Metoprolol,
Colistimethate for Inj, PMS-Brimonidine, Ratio-IPRA SAL UDV, Ratio-Lamotrigine,
Sab-Sodium Chloride, Sodium Aurothiomalate;
Declined: Apo-Flavaxate Tab 200mg, Pms-Flavoxate Tab 200mg;
New Limited Coverage Products: Apo-Cyclosporine Oral Sol, Apo-Indapamide, Apo-Mefloquine, Novo-Fluconazole,
Novo-Ticlopidine, Rabeprazole, Testosterone Cypionate Inj USP; New LCA Updates
Posted December 12, 2002
Alberta
Quarterly Update effective January 1, 2003
Highlights
New Products Added: Advair, Apo-Amoxi Clav, Apo-Clindamycin, Apo-Flavoxate, Apo- Floctafenine, Apo-Gliclazide, Apo-Lamotrigine,
Apo-Methazolamide, Apo-Zopiclone, Benztropine Omega, Cipro HC, CO Temazepam, Fluphenazine, Gen-Combo Sterinebs, Gen-Fluconazole,
Gen-Nizatidine, Gen-Warfarin, Lovenox, Novo-Fluconazole, Novo-Gabapentin, Novo-Levocarbidopa, Novorapid, PMS-Brimonidine,
PMS-Carbamazepine, PMS-Flavoxate, PMS-Fluconazole, PMS-Lovastatin, ratio-Amoxi lav, ratio-Brimonidine, Ratio-Lovastatin,
ratio-Sertraline, Thiamiject;
Changes to Benefit Status: Symbicort to Full Benefit Status effective January 1, 2003,
Andriol changes to a Special Authorization Benefit effective April 1, 2003;
New Special Authorization Products: Androderm, Aranesp, Fosamax 70mg, Apo-Cyclosporine 100mg;
Changes to Special Authorization Criteria: Exprex;
Deferred Products: Arixtra, Pegetron;
Products Not Added: Thyrogen, Xatral
Posted December 9, 2002
New Brunswick
Prescription Drug Program Formulary December 2002 Version
Highlights
Printed and electronic copies of the formulary are now available.
Posted December 6, 2002
New Brunswick
Update
Highlights
December 2002 Maximum Allowable Price List is published.
Posted November 29, 2002
British Columbia
Update
Highlights
Pharmacare introduces an enhancement to ensure prescriptions for long-term medications are not filled too soon.
Posted November 29, 2002
Newfoundland
Update November 2002
Highlights
Details on criteria for the coverage of special authorizaton drugs
Posted November 26, 2002
British Columbia
BC Newsletter November 25, 2002
Highlights
New Maximum Allowable Dispensing Fee: $8.25 effective December 1, 2002;
Discontinued PIN: 999105;
New Benefits: Monocur;
LCA Update: Tiazac;
Drugs Under Review: Kineret, Stemgen, Xatral, Lumigan, Botox, Plavix, DDAVP, Octostim,
Aricept, Teveten, Neupogen, Arixtra, Amaryl, Axmax Twisthaler, Pegetron, Pariet, Gluconorm,
Exelon, Protopic, Vagifem, Zelnorm, Androderm, Mavik, Rescula, Olanzapine
Posted November 26, 2002
Nova Scotia
November 2002 Bulletin
Highlights
Treatment of Vitamin B12 Deficiency with Oral Cyanocobalamin Therapy:
effective December 1, 2002: selected brands of oral Vitamin B12 will be insured as a full benefit in the Seniors' program.
For Cancer patients, oral Vitamin B12 will be an exception status drug.
effective March 1, 2003: the injectable form of Vitamin B12 will become an exception status drug for all Pharmacare Programs.A
miodarone, Cyclosporine and Warfarin Interchangeability between Generic and Innovator Brands effective November 15, 2002.
Revised Criteria for Exception Status Drugs used in the treatment of Osteoporosis: Fosamax Tablet,
Miacalcin Nasal Spray, Actonel Tablet, Evista Tablet
Posted November 18, 2002
Saskatchewan
Supplement to Bulletin #92 October 2002
Highlights
Changes to the Exception Drug Status criteria for Antibiotics: Clavulin,
Apo-Amoxi Clav-APX, ratio-Amoxi Clav-RTP, Zithromax, Suprax, Cefzil, Ceftin,
ratio-Cefuroxime, Apo-Cefuroxime, Cipro, Biaxin, Tequin, Levaquin, Avelox, Vancocin, pms-Vancomycin;
A new 2002 Antiobiotic Choices for Common Infectious Diseases chart is to be used in conjunction
with the criteria.
November 19, 2002
Alberta
Update Bulletin November 2002 effective October 1, 2002
Highlights
Product Supply Shortage: Diotrope 1% Ophthalmic Solution.
LCA temporarily assigned to Mydriacyl effective October 1, 2002.
Posted November 13, 2002
Nova Scotia
November Bulletin effective December 1, 2002
Highlights
DIN Changes effective December 1, 2002: Sofracort Ointment and Solution
Manufacturer Discontinued Products: Asendin, Betnesol, Choledyl SA,
Cortisporin, Declomycin, Diamox, Ephedrine, Feldene, Flagystatin, Glucagon,
Inderal, Inflasmase Mild, Isordil, Jectofer, Loxapac, Malogen in Oil, Miocarpine,
Nalfon, Neosporin Oph Oint, Novo-Gesic, Novo-Hydrocort, Orudis, Pilocarpine,
pms-Atenolol, pms-Cimetidine, pms-Propranolol, ratio-Synflex, Sibelium, Solganal,
Teveten, Tranxene, Versed, Accutrend Test Strips, Glucofilm, Glucostix,
Medisense Ultra, Unilet Lancets
November 11, 2002
NIHB
November 2002 Drug Bulletin Effective August 1, 2002
Highlights
New Open Benefits: Trizivir, Starlix;
New Limited Use Benefits: Xatral, Botox, Symbicort, Protopic
New Limited Use Benefit (Effective December 1, 2002): Unidet;
Not Listed: Fosamax, Dovobet, Aerius, NovoRapid, Xenical for new indication, Androgel;
Deferred Decision: Remicade;
Change in Benefit Status: Flomax will become a Limited Use Benefit effective January 1, 2003, Alphagan was an Open Benefit effective July 1, 2002.
Posted November 8, 2002
Nova Scotia
October Bulletin effective November 1, 2002
Highlights
New Exception Benefits: Fosamax, Protopic (Children .03%), NovoRapid, Xeloda;
New Diabetic Products Listed: SofClix Pro Lancets, Freestyle Lancets
Not Insured: Dovobet, Protopic (Adult .01%);
New Interchangeable Products: please see the bulletin;
New Exception Criteria: Remicade, Tamiflu;
Updated Wound Care Products Benefit List and Delisted Wound Care Prodcuts: please see the bulletin.
Posted November 6, 2002
New Brunswick
Bulletin 554 - Update effective November 1, 2002
Highlights
Benefit Additions: Novo-Fluconazole, Gen-Fluconazole, pms-Fluconazole, ratio-Amoxi Clav, Apo-Clindamycin, Apo-Mefloquine,
Novo-Levocarbidopa, Airomir, Apo-Salvent CFC Free, Combivent UDV, ratio-Ipra Sal UDV, Sibelium, Apo-Flunarizine, Fer-In-Sol,
Ferodan Infant Drops, Apo-Warfarin, pms-Lovastatin, pms-Lovastatin, ratio-Lovastatin, Apo-Clobazam, pms-Clobazam, Novo-Gabapentin,
Lamictal, Apo-Lamotrigine, Gen-Nefazodone, Novo-Nefazodone, Rhoxal-Sertraline, pms-Lorazepam, Apo-Nitrazepam, Co-Temazepam, Apo-Zopiclone,
Apo-Tobramycin, Neptazane, Apo-Methazolamide, Alphagan, ratio-Brimonidine, pms-Brimonidine, Gen-Nizatidine, Pediapred, pms-Prednisolone,
Apo-Gliclazide, Apo-Medroxy, Nizoral, Ketoderm, Diprosalic, ratio-Topisalic, Urispas, Apo-Flavoxate
Posted November 4, 2002
Alberta
Alberta Health & Wellness Drug Benefit List Additions effective October 1, 2002
Highlights
New Special Authorization: Flovent HFA
Posted November 1, 2002
British Columbia
Pharmacare Newsletter effective October 11, 2002
Highlights
CORRECTION: Butorphanal nasal spracy is not a Limited Coverage Drug as previously indicated on August 14, 2002.
Butorphanal is a non-benefit and is only considered on an exception basis.
New Benefits: Apo-Floctafenine, Ratio-brimonidine drops;
Non-Benefits: Meridia, Actos, Thyrogen, Cefzil, Starlix, Androgel, Dovobet;
Limited Coverage Drug: Glucagon;
Under Review: Kineret, Stemgen, Xatral, Lumigan, Monocor, Botox, Plavix,
Aricept, Teveten, Neupogen, Amaryl, Azmax, Pariet, Gluconorm, Exelon, Protopic, Vagifem, Rescula;
Multiple new LCA and/or RDP updates: please see the newsletter for more details.
Posted October 24, 2002
Québec
Update effective October 23, 2002
Highlights
Additions - Special Listings: Enbrel 25 mg pd. Inj. s.c.; Tracleer 125 mg & 62.5 mg Tabs;
Criteria Change: Gleevec; Remicade; Declined: Kineret 100 mg; Price Change: Eprex 10,000 IU/mL.
Posted October 17, 2002
Saskatchewan
Update Bulletin effective October 1, 2002
Highlights
New Exception Drug Status: Foxamax, Novo-Rapid, Starlix, Pariet;
New Strength New Exception Drug Status: biaxin 50mg (Oral suspension and ER Tablet),
Zyprexa 15mg Tablet, Unidet, 2 and 4mg ER Capsules;
New Full Benefits: Clindoxyl (topical gel), Premplus (tablet/package),
Apo-Erythro-Base 250mg tablet, Vagifem 25ug tablets, Glucagon 1mg powder,
pms-Ketoprofen 50mg suppository, Apo-Quinidine 200mg tablet;
Changes to Current Exception Drug Status Criteria: Fosamax 40mg tablet, Foradil 12ug capsule,
Oxeze Turbuhaler power/package, Antibiotics - see formulary for details;
Products Not Recommended: Dovobet, Nexium, Lipidil Supra, FXT 40, Kadian, Xemical, Ditropan XL,
Pariet, Androgel, Visudyne, Nasacort; Under Review: Kineret, Lumigan, Aranesp, Lovenox HP, Amaryl, Rescula;
De-listed Products effective April 1, 2003 Cefaclor, Detrol.
Posted October 17, 2002
New Brunswick
Formulary September 2002 Version
Posted October 10, 2002
Alberta
Update October 2002
Highlights
Due to the discontinuation of Neptazane 50mg tablets, Apo-Methazolamide 50mg tablets will be considered a temporary benefit and adjudicated to the pharmacy's actual acquisition cost until further notice under the AHWDBL. This temporary benefit will undergo the normal approval process in order to determine its future status.
Posted October 8, 2002
British Columbia
Changes to the Pharmacare Special Authority Process effective October 1, 2002
Highlights
Assumed Special Authorities are now being processed. Some medications will not qualify for the "Assumed Special Authorities."
Please visit the Pharmacare website for more details.
October 7, 2002
NIHB
Fall 2002 Update effective June 1, 2002 to October 1, 2002
Highlight
Additions to the Drug Benefit List:
June 1, 2002 Apo-Warfarin, Rhoxal-Cyclosporine;
July 1, 2002 Condom, Flovent HFA, Freestyle Glucometer, Freestyle Lancet, Freestyle Test Strip, Nu-Pravastatin,
PMS-Morphine Sulfate, PMS-Prednisolone, Premplus, Riva-Atenolol, Riva-Clonazepam, Rivacocet, Riva-Fluoxetine, Riva-Glyburide, Riva-Indapamide,
Riva-Metformin, Riva-Sotalol, Vantolin HFA; August 1, 2002 Apo-Flavoxate, Apo-Floctafenine, Apo-Gliclazide, Apo-Medroxy, DOM-Sertraline, PMS-Flavoxate,
PMS-Fluconazole, Starlix, Trizivir; September 1, 2002 PMS-Sertraline; October 1, 2002 Gen-Fluconazole, Gen-Propafenone, Ratio-Amoxi Clav, Ratio-Brimonidine, Ratio-Lovastatin;
Discontinued Drugs: Bicillin-LA, Maalox;
Limited Use Benefits Update: Botox Injection, Protopic, Symbicort, Xatral
Posted October 7, 2002
New Brunswick
New Maximum Allowable Price List - effective October 1, 2002
October 7, 2002
Newfoundland
New Interchangeable Drug List effective October 1, 2002
October 1, 2002
Québec
Formulary Version 12 effective October 1, 2002
Highlight
Hard copy and electronic version made available
October 1, 2002
Alberta
New Formulary version (hard copy made available) effective October 1, 2002
September 30, 2002
Alberta
Update effective October 1, 2002
Highlights
New Special Authorization Products: Cyclosporine
Posted September 27, 2002
Nova Scotia
September 2002 Bulletin
Highlights
New interchangeable products and Maximum Allowable Cost List Update: please see the bullletin for specifics.
September 18, 2002
Alberta
Quarterly Update effective October 1, 2002
Highlights
Products Added: Glucagon, Pariet, Apo-Medroxy, Apo-Misoprostol, Clindoxyl, Clobestasol Propionate, Estradot, Ketoderm,
Nu-Pravastatin, PMS-Prednisolone, Premplus, Ratio-Topisalic, Taro-Carbamazepine, Vagifem;
New Special Authorization Products: Valcyte;
Deferred Products: Dexiron, Infufer;
Products Not Added: Amaryl, Androgel, Dovobet, Lumigan, Starlix;
Devices Added as Restricted Benefits: Primeaire, Facial Masks for Use with Primeaire;
Products with Changes to SA Criteria: Rebetron, Rilutek;
Discontinued Products: Asendin,Choledyl SA, Glucagon, Inderal, Inflamase Mild, Isordil, Miocarpine, Miochol-E, Neptazane, Serax
Posted September 16, 2002
New Brunswick
Bulletin 547 - Update effective August 16, 2002
Highlights
New Benefit Addition: Flovent HFA;
Special Authorization Additions: Syvoxam, Tracleer, Tevetan, Ditropan XL;
Drug Reviewed and Not Listed: Prometrium
September 9, 2002
Newfoundland
August Formulary Version
September 9, 2002
Alberta
Update August 2002
Highlights
New LCA assigned: Pilocarpine HCL is Isopto Carpine,
and with the shortage of Diopentolate, a new LCA of Cyclogyl
for Cyclopentolate HCL has been temporarily assigned;
Updated list of PINS: see the bulletin for details.
Posted August 28, 2002
British Columbia
Pharmacare Newsletter August 14, 2002
Highlights
New Benefits: Ratio-Topisalic, Dexlron, Apo-Amoxi Clav, Premplus, Biaxin, Kadian,
Meoclopramide OMEGA, Dexamethasone OMEGA, Ratio-AMOXI clav, Sufentanil citrate;
Non-Benefits: Singulair, UNIDET, DIPHENISST OMEGA;
New Special Authority Benefits: Tracleer, Apo-Gliclazide,
PMS-Butorphanol, Apo-Zopiclone, PMS-Fluconazole, Gen-Fluconazole;
Drugs Under Review: Kineret, Stemgen, Xatral, Lumigan,
Monocor, Botox, Plavix, Aricept, Teveten, Neupogen, Amaryl, Azmax, Pariet,
Gluconorm, Exelon, Protopic, Vagifem, Rescula;
LCA Updates: see manual for details.
Posted August 27, 2002
Nova Scotia
August Bulletin effective September 1, 2002
Highlights
New Products (Benefits) Added: Diamicron MR, Apo-Warfarin, Glucagon, Kadian, Monocor, Remeron, Travatan, Vaseretic;
New Exception Status Drugs: Seroquel;
Changes in Benefit Status (Exception to Full Benefit): Arthrotec;
Not Insured Products: Aerius, Allegra, Copaxone;
Exception Status Criteria Modification Plavix;
MAC List Changes: Cyanocobalamin, Oxycodone (see the MAC Listing in binder for details)
Posted July 30, 2002
New Brunswick
June 2002 Formulary Version effective June 1, 2002
Posted July 25, 2002
Manitoba
Bulletin #37 - effective July 22, 2002
Highlights
New Benefits: Alti-Morphine Sulfate SR, Apo-Alpraz, Apo-Ipravent,
Apo-Ketoralac, Apo-Salvent, Dexiron, Gen-Warfarin, Infufer, pms-Hydromorphone,
pms-Nefazodone, pms-Sertraline, Rhoxal-Sertraline;
Changes to Criteria: Plavix;
New Special Request Drugs: Rhoxal-Nabumetone, Rhoxal-Oxaprozin;
Product Deletions: Aquacort, Corium, Cortone, Decadron Phosphate,
Elavil, Nu-Medopa, pms-Clobazem, Serax, Urecholine;
Discontinued Products: Elavil Pamoate, Flexeril, Hydrodiuril,
Intal, Loxapac, Myambutol, Noroxin, Norventyl, Reglan, Surgam, Tolectin,
Ultradol;
Multiple New Interchangeable Categories: please see the bulletin.
Posted July 18, 2002
Nova Scotia
July Bulletin effective August 1, 2002
Highlights
New Maximum Allowable Cost List; Discontinued Products; DIN Changes. Please see Formulary for details.
Posted July 8, 2002
British Columbia
Pharmacare Newsletter June 27, 2002
Highlights
New Benefits: Acetylcysteine Solution;
Non-Benefits: Clindoxyl, Nexium;
Special Authorization Only: Ketoderm, Tracleer
July 8, 2002
Saskatchewan
Update Bulletin July 2002
Highlights
New Exception Drug Status: Symbicort Turbuhaler, Videx EC, Copaxone, Advair;
New Full Benefit Listing: Xatral, Freestyle, Rosasol;
Modifications to Exception Drug Status Criteria: Arava, Enbrel, Remicade, Zyvoxam;
Not Recommended for Listing: Kadian;
Delisted: Apo-Fenofibrate, Nu-Fenofibrate (patients who currently have exception status coverage will continue to be covered);
First Entry Generic: Apo-Lamotrigine
Posted July 5, 2002
Ontario
ODB Update 4, No. 37 - effective July 29, 2002
Highlights
Please see the update for details.
New Full Benefit Products: Alti-Salbutamol HFA, Flovent HFA, Pariet,
Remeron, Rosasol, Seroquel, Apo-Clindamycin, Apo-Desmopressin, Apo-Favoxate,
Apo-Floctafenine, Gen-Hydroxyurea, Novo-Levocarbidopa, Novo-Misoprostol,
Nu-Pravastatin, PMS-Divalproex, Ratio-Methotrexate Sodium, Ratio-Morphine SR,
Rhoxal-Amiodarone; New Limited Use Products: Aromasin, Atacand Plus,
Estradot, Micardis Plus, Teveten, Travatan, Apo-Gabapentin, Apo-Ipravent,
Novo-Gabapentin, PMS-Clobazam;
Discontinued Products: Ultra Plus, Amoxil, Asendin, Atropisol, Bicillin,
Jectofer, Loxapac, Mellaril, Miocarpine, Motilium, Myambutol, Novo-Timol,
Potassium-Sandoz, Robidone, Serax, Serentil, Tolectin, Tolectin DS, Tomycine,
Triadapin;
Delisted Drugs: Amitriptyline, Chloral Hydrate, Chlordiazepoxide,
Chloromycetin, Colchicine, Hydrochlorothiazide, Imipramine, Oxazepam, Perphenazine,
Propranolol, Sulfamethoxazole & Trimethoprim, Thioridazine, Tlbutamide, Trifluoperazine;
Not a Benefit: Rheumatrex; Status Change from general to limited use: Zoloft capsules
July 3, 2002
Alberta
Update June 2002
NOTICE:
Effective October 1, 2002 weight loss products including Xenical will
not be eligible for coverage. As well, due to a supply shortage resulting
from the discontinuance of Glucagon 1mg/vial injection, the new fomulation
of Glucagon, RDNA 1mg/vial injection will be added to the Benefit List as
a temporary benefit effective June 1, 2002.
Posted June 28, 2002
Nova Scotia
June Bulletin effective July 1, 2002
Highlights
New Exception Status Products: Tracleer, Ditropan XL, Zyvoxam;
New Products Added: Flovent HFA, Teveten;
Not Recommended: Prometrium
June 24, 2002
Alberta
Quarterly Update effective July 1, 2002
Highlights
New Special Authorization: Protopic;
New Restricted Benefit: Symbicort;
Products Not Added: Ditropan XL, Meridia, Xenical, Nexium, Renagel, Remicade for treatment of Crohn's Disease;
Deferred Products: Foxamax, Enbrel and Remicade;
Products Added: Apo-Azathioprine, Apo-Cefuroxime, Apo-Fluphenazine, Apo-Gabapentin, Apo-Ketorolac, Gen-Nabumetone,
Kadian, Midazolam, Plan B, PMS_Fluorometholone, PMS-Morphine Sulfate, PMS-Nefazodone, PMS-Sertraline, Rho-Nitor Pumpspray,
Rhoxal-Nabumetone, Rhoxal-Sertraline, SAB-Pentasone, Testosterone Cypionate, Triamcinolone Acetonide;
Discontinued Listings: Albert Oxybutynin, Alti-Doxepin, Corium, Fexicam, Micocarpine, Motilidone, Norventyl, Sotamol,
Theophylline, Tolectin-600, Ultradol.
June 21, 2002
Québec
Update to April 2002 Veriosn effective July 1, 2002
Highlights
Additions - Full listings: PMS-Morphine Sulfate SR tabs; PMS-Nefazodone tabs;
PMS-Sertraline caps.; Abenol supp.; Advair 125; Advair 250; Apo-Clindamycin caps.; carbocal D 400 UI caps; Colistimethate pd. inj.;
Dexiron; Euro-K 8 caps LA; Freestyle; Gen-Nabumetone tabs; Gen-Warfarin tabs; Glucagon pd. inj.;
Unfurer sol. inj.; Prestige; Rhoxal-Cyclosporine caps; Rhoxal Nabumetone tabs; Rhoxal-Sertraline caps; Riva-K 20 SR tabs.
Additions - Special listings: Amaryl tabs; Aquaflo Disque pans.;
Compleat Pédiatrique liq. ; Copaxone Inj.; Curafoam pans., Curagel pans.;
Curasalt Pans.; Midazolam Sol. inj.; Oesclim 25; Oesclim 50; peptamen fos/inculin; Peptinex;
peptinex DT; Promote; Symbicort 100 Turbohaler pd. inh; Tielle pans.; Trileptal tabs; Twocal HN;
Ultec pans.; Unidet caps. LA.
Modifications:Please see the update for status changes, de-listings and other modifications.
Posted June 3, 2002
Nova Scotia
May Bulletin effective June 1, 2002
Highlights
New Exception Status Products:Tequin, Avelox;
Delisted Product: Rogitine;
New Listings: Gen-Warfarin, FreeStyle Blood Glucose Test Strips, Prestige Blood Glucose Test Strips;
New Interchangeable Categories: Please see the bulletin;
Modifications to Existing Interchangeable Categories: Please see the bulletin
Posted May 15, 2002
New Brunswick
Bulletin 540 - Effective May 17, 2002
Highlights
Special Authorization Additions: Aldara, Arava, Zanaflex, Tryptan;
Special Authorization Revised Criteria: Urso;
Not Recommended for Listing: Nexium, FemHRT;
Full Benefit Additions: Salofalk, Mirena
Posted May 15, 2002
British Columbia
Newsletter effective May 9, 2002
Highlights
Correction to Imfliximab Special Authorization dates April 19, 2002.
New Additions: Dimethyl sulfoxide irrigation USP; Taro-Carbamazepine, Travatan,
Prestige blood glucose test strips; Not Recommended: Rhoxal-Oxaprozin, Estalis,
Reminyl, Peg-Intron, Apo-Ketorolac injectable; LCA Updates: please see the newsletter;
New Special Authorization Drugs: Symbicort, Comtan, Rhoxal-Navumetone, Fosamax, Advsir,
Copaxone, Apo-Salvent, Apo Ipravent sterules.
Posted May 15, 2002
Newfoundland
Benefit List effective May 13, 2002
Posted May 6, 2002
Nova Scotia
Bulletin April 2002
Highlights
New Exception Status Drugs Criteria: Actos, Avandia, Remicade, Enbrel, Arava;
Discontinued Products: Anapolon, Asendin, Bicillin, Cardene, Demadex,
Disalcid, Disipal, Empracet-60, Fansidar, Intal, Isuprel, Loxapac, Ludiomil,
Methotrexate, Miocarpine, Motilium, MSD EC ASA, Mycostatin, Naprosyn, Phospholine Iodide,
Pronestyl, Quinidex, Reglan, Taro-Etodolac, Theolair, Tridil, Ultradol, Verapamil
Posted May 3, 2002
Saskatchewan
Quarterly Update April 1, 2002
Highlights
New Expection Drug Status:
Trizivir-GSK, Tracleer-AC, Hectorol-DPY, Fucithalmic-LEO, Aredia-NVR, Protopic-FUJ;
New Exception Drug Status Strength/forms: Singulair-MSD, 4mg, Seroquel-AST, 300mg;
First Entry Generic: Apo-Amoxi Clav-APX, Apo-Floctafenine-APX, pms-Fluorometholone-PMS,
SAB-Pentasone; Modifications to Current Exception Drug Status Criteria: Rocaltrol-HLR,
Duragesi-JAN, Singulair-MSD, Cellcept-HLR, Zprexa Zydis-LIL, Seroquel-AST, Gluconorm-NOO, Urso-AXC;
New Full Listings: Epi-Pen Jr.-ALX, Epi-Pen-ALX, Sof-Tact-MDC, Plan B-PAL, Alti-morphine SR-ALT,
Tazorac-ALL, Travatan-ALC; Discontinued Products: Jectofer-AST, Tolectin-JAN;
Not Recommended for Listing: Diamicron MR-SEV, Carnitor-SIG
Posted May 2, 2002
Manitoba
Bulletin #36 - Effective May 1, 2002
Highlights
Additions: Alti-Methotrexate Sodium, Alti-Timolol Maleate, Atacand Plus, Gen-Nitro,
Novo-Gabapentin, Novo-Levocarbidopa, Novo-Misoprostol, pms-Clobazam, pms-Doxazosin, pms-Fluoorometholone,
pms-Misoprostol, Rhoxal-amiodarone, Rhoxal-ranitidine, sab-Pentasone, Valtaxin, Vaseretic;
Special Requests: Codeine Contin, Diamicron MR, Reminyl;
Product Deletions: Apo-Ipravent, Loxapac, Miocarpine, Myambutol, Quinidine Sulfate, Robidone;
Multiple Discontinued Products: please see the bulletin; Interchangeable Product Price Changes: please see the bulletin;
New Interchangeable Products and Categories: please see the bulletin; Manufacturer Updates: please see the bulletin.
Posted April 29, 2002
British Columbia
Pharmacare Newsletter dated April 22, 2002
Highlights
New Special Authorization Products: Infliximab, Etanercept
Posted April 16, 2002
Nova Scotia
Pharmacare April Bulletin effective April 15, 2002
Highlights
New Exception Status Drugs Added: Actos, Arava,
Avandia, Enbrel, Remicade, Zanaflex;
New Benefits Added to Senior and Community Services: Gen-Nitro;
New Benefits Added to Community Services: Mirena;
New Benefits Added to Seniors, Community Services and Diabetic Assistance Program: Lifescan Ultra Soft Lancets, Precision Plus Electrode Test Strips;
Not Insured: Nexium;
Removed from Diabetic Supplies Benefit List: Disposable Needles various sizes, Precision QID with Electrodes, Precision QID without Electrodes,
Smart Strip Blood Glucose Test Strip; Maximum Allowable Price Updates: please see the bulletin.
Posted April 8, 2002
British Columbia
Pharmacare Newsletter March 22, 2002
Highlights
Benefit Status Change from SA to Full Benefit: Alphagan, Azopt, Trusopt, Xalatan, Cosopt;
New Full Benefits: Sab-Pentasone, Apo-Cefuroximate, Flovent HFA, RHO-Nitro Pumpspray, Mirena, Azmax,
Non-Benefit Status: Tamiflu, Fucithalmic, Androderm, Miacalcin;
New Special Authorization: Gen-Hydroxyurea, Rhoxal, Zyvoxam.
The newsletter also includes LCA Updates and new products categorized to LCA or RDP.
Posted April 4, 2002
Nova Scotia
Special Bulletin dated March 28, 2002
Highlights
New Tariff Levels (professional fees)
have been published for the April 1, 2002 to March 31, 2003.
For prescriptions with a drug ingredient cost of up to $125.00: maximum of $9.35;
prescriptions with a drug ingredient cost of more than $125.00: maximum of $14.02
April 1, 2002
Québec
New Formulary Edition effective April 1, 2002
Highlights
Additions - Full listings: NovoRapide s.c. inj. sol. 100 U/mL (3 mL);
Travatan oph. sol. 0.004%; Trizivir tab. 300-150-300 mg; Additions - Special listings: Humalog Mix 25 insulin lispro protamin
susp. inj. s.c. 25%-75% (3 mL);
Declined: Meridia caps 10 mg and 15 mg; Remicade pd. inj. i.v. 100 mg;
Starnoc caps. 5 mg and 10 mg; Videx caps. 125 mg, 200 mg, 250 mg, and 400 mg; Status change from special to full listing:
Aromasin tab 25 mg; Change in listing criteria: Gleevec caps 100 mg; Re-evaluated for listing: Agenerase caps 50 mg and 150 mg and oral sol. 15 mg/mL.
March 20, 2002
Alberta
New Formulary Edition effective April 1, 2002 and Update
Highlights
New Products Added: Travatan, Metadol-D, Rosasol;
Changes to SA Criteria: Dostinex, Rilutek;
Products Not Added: Fucithalmic, Starnoc;
Deferred Products: Enbrel, Protopic, Renagel
Posted March 11, 2002
Ontario
ODB Update to Edition 37 effective April 4, 2002
Highlights
Additions: Agenerase, Hydromorph Contin, Lipitor Premplus, Seroquel, Alti-Cefuroxime, Apo-Cefuroxime, Apo-Misoprostol, Benztropine Omega, Novo-Fenofibrate Micronized, PMS-Doxazosin, PMS-Lorazepam, PMS-Misoprostol, Sab-Tobramycin, Taro-Warfarin, Tobramycin;
Limited Use Additions: Codeine Contin, Estalis-Sequi, Flomax, Reminyl, Rhoxal-Ticlopidine;
Numerous Manufacturer Requested Discontinued Products: see update for listing or consult with iMAM;
Discontinued Diabetic Testing Agent: Ultra +; Delisted Drug: Zithromax, Acetest, Ketostix;
Limited Use Changes: Cipro, Duragesic, Oxycontin, Prograf;
Posted March 3, 2002
Manitoba
Bulletin #35 - Effective February 28, 2002 and Current Benefit List
Highlights
Additions: Diclectin, Hydromorph Contin, Lipitor (80mg), Teveten;
Amendments to Special Authorization: Mobicox - not covered for Acute Pain, Plavix, Serc, Zomig Rapimelt;
Additions to Special Authorization: Mirena, Prograf, Zyvoxam;
Not Listed: Androderm, Zenapax; Multiple Interchangeable Product Price Changes
Posted February 27, 2002
New Brunswick
Bulletin 537 - effective March 13, 2002 and Product Updates Volume 43 effective February 2002
Highlights
Interchangeable Product Additions:
Drug products have been added to the interchangeable pharmaeutical products list.
Note these changes do not necessarily reflect changes in drug benefit plan formularies.
Apo-Cefuroxime, Methotrexate, Alti-Methotrexate, Apo-Salven Sterules, Norflex, Rhoxal-Orphenadrine,
Rhoxal-Amiodarone, Rythmol, Apo-Propafenone, pms-Propafenone, pms-Doxazosin, Nitrolingual,
Gen-Nitro SL Spray, MS Contin, Alti-Morphine Sulfate SR, Apo-Gabapentin, Apo-Alpraz TS, Garasone,
SAB-Pentasone, Alti-Timolol, Cytotec, Apo-Misoprostol, Novo-Misoprostol, Rhoxal-Ranitidine, Monistat 7,
Monazole 7, Apo-Azathioprine
Posted February 25, 2002
Nova Scotia
Pharmacare Bulletin - effective April 1, 2002
Highlights
Changes to the Nova Scotia Seniors' Pharmacare Program:
The annual premium will increase from $215 to $336.
The income levels for premium reductions will increase:
Single Seniors: annual income below $l7,000 = no premium payment,
annual income between $17,000 and $24,000 = partial redution in premium.
Married Seniors: combined annual income is below $20,000 = no premium payment,
combined annual income between $20,000 and $28,0000 = partial reduction in premium.
February 20, 2002
Alberta
Update - effective March 2, 2002
Highlights
Plavix available as a Limited
Restricted Benefit effective March 2, 2002.
This means that Special Authorization is not required for Plavix coverage when the
medication is prescribed by a designated prescriber under the specific conditions.
Posted February 13, 2002
Manitoba
Bulletin #34, effective February 11, 2002
Highlights
Product Additions:
Accu-Check Compact, A-Hydrocort, Apo-Fluphenazine, Apo-Gabapentin, Apo-Ipravent, Apo-Misoprostol,
Apo-Propafenone, Co Fluoxetine, Dimethyl sulfoxide, Gen-Hydroxyurea, Haloperidol Long Acting,
Hydrocortisone Sodium Succinate, Nu-Pravastatin, Penlet Plus Adjustable Blood Sample, pms-Divalproex,
pms-Lorazepam, Sof-tact, Solu-Cortef, Triacmb, Ultra Soft Lancet;
Amendments: Alti-Cefuroxime, Apo-Amoxi Clav, Apo-Cefuroxime, Climara, Estalis, Estracomb, Estraderm,
Estrogel, Oesclim, Vivelle, Duragesic, Rhoxal-ticlopidine;
New Exception Drugs: Apo-Oxaprozin, Rapamune, Renagel;
Non-Benefit: Tamiflu;
Product Deletions: Virostat, Bisacolax, Chlorpromanyl 20, Decongest, Isordil, Miocarpine;
Discontinued Products: see bulletin for list;
New interchangeable products and categories: see bulletin for list;
Update to Drug Submission Requirements new authorization letter template.
February 8, 2002
Alberta
Addition to AHWDBL effective February 1, 2002
Highlights
Product Addition: Alti-Morphine Sulfate SR;
New Interchangeable Product Grouping: Morphine Sulfate, LCA price policy will be applied effective April 1, 2002.
February 5, 2002
Newfoundland
New Benefit Listing, January 29, 2002 and New Interchangeable Drug Formulary, January 30, 2002
Posted February 1, 2002
Nova Scotia
2002 Formuary - January 2002
Highlights
New formulary updates
Posted February 1, 2002
Nova Scotia
Bulletin - January 28, 2002
Highlights
Maximum Allowable Cost Price adjustments.
Posted January 28, 2002
New Brunswick
Bulletin - January 25, 2002
Highlights
Benefit Additions: Salbutamol Sulfare, Nifedipine,
Ibuprofen, Hydromorphone Hydrochloride, Clotrimazole, Calcipotriol; Special Authorization
Additions: Serc, Cipro, Monurol, Actos, Seroquel, Rebetron, Rapamune; Benefit Status Changes:
Adalat XL to regular benefit, Cipro to special authorization, ranitidine to regular benefit
for beneficiaries age 65 and over.
Posted January 28, 2002
British Columbia
Newsletter January 23, 2002
Highlights
Maximum allowable dispensing fee has increased to
$7.80 effective January 15, 2002. Notice of error: Betaxolol Solution .25% and l5% were
reported as discontinued in error. Numerous products under review.
Posted January 21, 2002
Nova Scotia
January 2002 Bulletin
Highlights
Maximum Allowable Cost List (New and Updates) effective February 1, 2002; Discontinued Products, DIN Change, New Physician and Optometrist Lists
January 16, 2002
Newfoundland
New Benefit Listing, January 8, 2002
Posted January 10, 2002
British Columbia
Newsletter December 21, 2001
Highlights
New benefits: Apo Gabapentin, Novo-Misoprostol, Seroquel, Premplus, Alti-Methotrexate, Remeron, Declined: Apo-Oxaprozin, Special Authority: Tazorac, Diamicron, DDAVP
Posted January 10, 2002
British Columbia
Newsletter December 21, 2001
Highlights
New benefits: Zithromax, Gen-Nitro Spray, Alti-Cefuroxime, Rosal cream, PMS-Deferoxamine, Declined: Hectorol, FemHRT, Tequin, Cefazolin, Special Authority: Estrogel
Posted January 07, 2002
Alberta
Update - January 1, 2002
Highlights
New special authorization product: Reminyl (Galantamine Hydrobromide)
January 02, 2002
Saskatchewan
Quarterly Update January 1, 2002
Highlights
New Exception Drug Status: Infliximab injection, Estradiol,
Linezolid, Meloxicam, Sevelamer, Galantamine hydrobromide; Full Status: Fenofibrate, Dihydroergotamine
mesylate, Atorvastatin calcium, Betahistine HC1, Candesartan cilexetil/hydrochlorothiazide, Enalapril
maleate/hydrochlorothiazide, Entacapone, Glucose oxidase/peroxidase reagent, Hydromorphone HC1, Mirtazapine,
Telmisartan/hydrochlorothiazide; Changes to current exception durg status criteria: please see the update;
Not Listed: Lipidil Supra-FFR tab 100mg, Tamiflu-HLR capsule, 75mg, Ditropan XL-JAN tab 5mg, 10mg, Rilutek-AVT,
Androderm-PAL
|
